Lipofectamine

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

Retrieved on: 
Monday, January 30, 2023
Transfer, Biomedical Advanced Research and Development Authority, RNA, Necessity and sufficiency, Disease, Lipofectamine, Food, Phase II, Safety, Oligonucleotide, Mycosis, Attention, HeLa, Mucormycosis, NYSE, BioNTech, Gene expression, Evaluation, Mucor, Sirna, Vaccine, ASO, Cryptococcosis, Aspergillosis, Survival, Therapy, Conference, Gilead, BARDA, Internal, COVID, HEK293, Patient, Enactment, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Aspergillus, LNC, Organic acid, Hand, Candidiasis, Genentech, Coccidioidomycosis, Medicine, Asos, Development, RNA transfection, Sirna Therapeutics, Toxicity, Fine chemical, Pharmaceutical industry, Matina Brothers

ET

Key Points: 
  • ET
    BEDMINSTER, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB, Matinas), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today is providing a business update on its ongoing programs and discussing its strategic outlook for 2023.
  • Our ongoing collaborations with BioNTech and, recently, National Resilience, have aligned Matinas with two of the world’s leading companies in the gene therapy space.
  • The Company will host a live conference call and webcast to discuss this corporate update and 2023 business outlook today, Monday, January 30 at 4:30 p.m.
  • The live webcast will be accessible on the Investors section of Matinas BioPharma’s website, www.matinasbiopharma.com , and archived for 90 days.

Crossing Blood-Brain Barrier: Delivery of Biomolecules into Glioblastoma Enabled by Altogen's Nanoparticle In Vivo Transfection Reagent

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Biology, Molecular biology, Life sciences, Biotechnology, Gene delivery, RNA, Laboratory techniques, Transfection, Small interfering RNA, Electroporation, Lipofectamine

In 2018 Altogen Biosystems launched the AltoFect transfection reagent formulated for difficult-to-transfect cells (like B-cells, T-cells), and primary cell cultures that are known to be resistant to most typical transfection technologies.

Key Points: 
  • In 2018 Altogen Biosystems launched the AltoFect transfection reagent formulated for difficult-to-transfect cells (like B-cells, T-cells), and primary cell cultures that are known to be resistant to most typical transfection technologies.
  • Company offers over 120 cell-line specific transfection kits, optimized electroporation products, and in vivo transfection reagents that are used for tissue-targeted delivery of negatively charged biomolecules (siRNA/miRNA, mRNA, plasmid DNA, small proteins, etc).
  • Altogen Biosystems announced that its Nanoparticle-basedIn VivoTransfection Reagent was used for effective overcoming blood-brain barrier and successful transfection of glioblastoma tumor cells with both plasmid DNA and siRNA molecules.
  • Altogen's nanoparticle in vivo transfection reagent was referenced in over 40 research publications for effective in vivo delivery of biomolecules, however Altogen scientists still had to develop modified in vivo transfection protocol to enable brain-targeted delivery.

Altogen Biosystems Launched cGMP-grade Nanoparticle Transfection Reagent for In Vivo Delivery

Retrieved on: 
Thursday, May 31, 2018
Biology, Molecular biology, Gene delivery, Biotechnology, Biochemistry, Applied genetics, Transfection, Pre-clinical development, Altogen Inc., Lipofectamine

In vivo reagent offers high transfection efficiency, reproducibility, robustness and represent a novel promising approach for medical applications such as gene and oligonucleotides therapy.

Key Points: 
  • In vivo reagent offers high transfection efficiency, reproducibility, robustness and represent a novel promising approach for medical applications such as gene and oligonucleotides therapy.
  • Nanoparticle In Vivo Transfection Reagent was selected as the delivery vehicle of choice in several drug development programs.
  • For this purpose, Altogen Biosystems provides a cGMP grade transfection reagent required for clinical trials.
  • Altogen Labs , a GLP-compliant preclinical research laboratory, completed preclinical testing of Nanoparticle In Vivo Transfection Reagent.